Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2600 • ACR Convergence 2024
Repression of the Aryl-hydrocarbon Receptor Prevents Oxidative Stress and Ferroptosis of Intestinal γδT Cells and Alleviates Systemic Lupus Erythematosus
Qiaolin Wang¹, Yutong Wu², Qianjin Lu¹ and Ming Zhao¹, ¹Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China (People's Republic), ²Department of Dermatology, Hunan Key Laboratory of Medical Epigenomics, Second Xiangya Hospital, Central South University, Nanjing, China (People's Republic)
Background/Purpose: Dysregulation of intestinal γδT cells orchestrates the pathogenesis of various autoimmune disorders, however, its involvement in systemic lupus erythematosus (SLE) etiology remains elusive.Methods: Employing single-cell sequencing, we…
Abstract Number: 2680 • ACR Convergence 2024
Thrombocytopenia in Patients with Systemic Lupus ErythematosusReal-World Data Based on a Nationwide Database, RISE
Omer Pamuk¹, Jessica Fitzpatrick², Jing Li³, Gabriela Schmajuk⁴ and Marina Magrey⁵, ¹University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ²University California, San Francisco, San Francisco, CA, ³University of California, San Francisco, San Francisco, CA, ⁴UCSF / SFVA, San Francisco, CA, ⁵Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease with a very heterogeneous presentation. Thrombocytopenia (TP) is an infrequent presentation in patients with SLE…
Abstract Number: 0087 • ACR Convergence 2024
SYNCAR: An Engineered IL-2/IL-2R-system That Selectively Enhances CD19 CAR T Cells to Deplete B Cells and Provide Therapeutic Benefit in SLE and RA Mouse Models Without Lymphodepletion
Ethan Jung¹, Marie semana¹, Ivan Cheng¹, Helena Silva¹, Sandro Vivona¹, Somya Singh¹, Michele Bauer¹, Mohammed Ali¹, Henry Rosas¹, Woei Chang¹, Deepti Rokkam¹, Patrick Lupardus¹, Martin Oft¹ and Paul-Joseph Aspuria², ¹Synthekine, Menlo Park, ²Sythekine, Menlo Park, CA
Background/Purpose: CD19 CAR-T therapy has demonstrated efficacy in autoimmune (AI) diseases like systemic lupus erythematosus (SLE) and lupus nephritis (LN), showing its potential beyond oncology.…
Abstract Number: 0159 • ACR Convergence 2024
Prevalence and Potential Factors Associated with Polypharmacy in Individuals with Systemic Lupus Erythematosus
Jianing Yang¹, Jinoos Yazdany², S. Sam Lim³, Brad Pearce³ and Laura Plantinga⁴, ¹Highland Hospital, AHS, San Leandro, CA, ²UCSF, San Francisco, CA, ³Emory University, Atlanta, GA, ⁴University of California, San Francisco, San Francisco, CA
Background/Purpose: Polypharmacy is associated with an increased risk of adverse drug effects and medication nonadherence. However, the prevalence of polypharmacy and the medications and factors…
Abstract Number: 0188 • ACR Convergence 2024
Social Support in African American Women with and Without Systemic Lupus Erythematosus (SLE)
Sarah Smith¹, Chloe Mattila¹, Charmayne M. Dunlop-Thomas², Lusawasra King³, Lori Ann Ueberroth³, Edith Williams⁴, S. Sam Lim⁵, Diane Kamen³, Bethany Wolf³ and Paula Ramos³, ¹Medical University of South Carolina, Charleston, ²Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, ³Medical University of South Carolina, Charleston, SC, ⁴University of Rochester School of Medicine and Dentistry, Rochester, ⁵Emory University, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionately impacts African American women. However, this health disparity population continues to be underrepresented in research. Research suggests that social…
Abstract Number: 0318 • ACR Convergence 2024
The Relevance of a Positive ANA in New Patient Referrals to Rheumatology
Chi Chi Lau¹ and Ayesha Arif², ¹University of Vermont Medical Center, colchester, VT, ²University of Vermont Medical Center, Essex Junction, VT
Background/Purpose: A positive (+)ANA titer is a common reason for Rheumatology consultation, yet the ANA is a nonspecific, non-diagnostic, lab test that is positive in…
Abstract Number: 0439 • ACR Convergence 2024
Contraception Counseling and Contraception Use Among SLE and RA/JIA Patients at a Public Medical Center in Los Angeles: Investigating Teratogenic Medication Use and Language Preferences
Laura Kobashigawa¹, Cassidy Hernandez-Tamayo², Katherine Ruddy³, Melissa Wilson² and Leanna Wise⁴, ¹University of Southern California/Los Angeles General Medical Center, Pasadena, CA, ²Keck School of Medicine of USC, Los Angeles, CA, ³University of Southern California/ Los Angeles General Medical Center, Los Angeles, CA, ⁴LAC+USC/Keck Medicine of USC, Pasadena, CA
Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)/juvenile idiopathic arthritis (JIA) frequently impact women of reproductive age. Management of these patients is particularly important…
Abstract Number: 0615 • ACR Convergence 2024
Socioeconomic Determinants of Lupus Hospitalization Outcomes: A Review of Current Knowledge and Analysis of the 2016-2019 NRD Database
Akhila Arya P V¹, Madhumitha Rondla², Jai Juganya Tirupur Ponnusamy³ and Dileep C Unnikrishnan⁴, ¹Bridgeport Hospital, Stratford, CT, ²Texas tech university health sciences center, El paso, El Paso, TX, ³Metrowest Medical Center, Framingham, ⁴Bridgeport Hospital, Bridgeport, CT
Background/Purpose: Hospitalizations due to systemic lupus erythematosus (SLE) often stem from lupus flares and infections. Socioeconomic factors influencing outcomes in SLE hospitalizations have been studied…
Abstract Number: 0633 • ACR Convergence 2024
Novel LINE-1 Reverse Transcriptase Inhibitors Can Suppress Type I Interferon Responses and Are Promising Therapeutics for Lupus
Wenyan Miao¹, Digna de Bruin², Cedric Arisdakessian¹, Jannik Rousel², Jared Steranka¹, Matthijs Moerland², Eric Jacobson¹, Mehrnaz Gharaee-Kermani³, Liyang Diao¹, Craig Dobry³, Nafeeza Hafeez¹, Brian Desrosiers¹, J. Michelle Kahlenberg³, Heike Keilhack¹, Robert Rissmann², Keith M Wilcoxen¹ and Tessa Niemeyer-van der Kolk², ¹Rome Therapeutics, Boston, MA, ²Centre for Human Drug Research, Leiden, Netherlands, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Long Interspersed Element-1 (LINE-1) retrotransposon encodes for two proteins, ORF1p and ORF2p. ORF1p is a chaperone protein while ORF2p contains reverse transcriptase (RT) and…
Abstract Number: 0652 • ACR Convergence 2024
Analysis of Relapses in a Single Center Cohort of Patients with Lupus Nephritis
Gamze Kemec¹, Sibel Varelci², Erdem Gurel², Isın Kılıcaslan³, Yasemın özlük³, Yasemın Yalcınkaya⁴, Ahmet Gul⁵, Murat Inanc⁶ and bahar Artım Esen⁴, ¹Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine Istanbul Faculty of Medicine, Istanbul, Turkey, ³Department of Pathology Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Division of Rheumatology, Department of Internal Medicine, Istanbul, Turkey, ⁵Division of Rheumatology, Department of Internal Medicine, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, Istanbul, Turkey, ⁶Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Relapses are correlated with increased hospitalizations, poor renal outcomes, morbidity and mortality. We aim to investigate the incidence, predictive factors and outcomes related to…
Abstract Number: 0670 • ACR Convergence 2024
A Randomized, Open-Label, Phase III Trial Comparing Efficacy and Safety of Intravenous Cyclophosphamide, Mycophenolate Mofetil, or Tacrolimus as Induction Therapy in Lupus Nephritis
Alekhya Amudalapalli, Ashlesha Shukla, Abhichandra Maddineni, Sandeep Nagar, Sudhish Gadde, Harish BV, Rashmi Ranjan Sahoo and Pradeepta Sekhar Patro, IMS and SUM Hospital, Bhubaneswar, India
Background/Purpose: The optimal treatment for lupus nephritis is challenging due to its heterogeneity and the lack of prognostic factors favoring one immunosuppressive drug over another.…
Abstract Number: 0843 • ACR Convergence 2024
External Validation and Extension of Population-Based Systemic Lupus Erythematosus Risk Prediction Models Using Genetics, and Lifestyle and Environmental Factors
Jacob J.E. Koopman¹, Jing Cui¹, Hongshu Guan¹, Emma Stevens¹, Emily Oakes¹ and Karen Costenbader², ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital/ Harvard Medical School, Boston, MA
Background/Purpose: Many genetic and environmental risk factors for SLE are now known. We have developed SLE risk prediction models, incorporating known genetic, lifestyle, and environmental…
Abstract Number: 1037 • ACR Convergence 2024
Recommendations for the Perioperative Use of DMARDs in Rheumatic Diseases: A Scoping Review
Alice Terrett¹, Athena Chin², Mihye Kwon³, Samuel Whittle⁴ and Catherine Hill⁵, ¹The Queen Elizabeth Hospital, Adelaide, Australia, ²Royal Adelaide Hospital, Tranmere, South Australia, Australia, ³Konyang University, College of Medicine, Daejeon, Republic of Korea, ⁴The Queen Elizabeth Hospital, Springfield, South Australia, Australia, ⁵The Queen Elizabeth Hospital, Woodville, South Australia, Australia
Background/Purpose: The use of disease-modifying anti-rheumatic drugs (DMARDs) in the treatment of autoimmune rheumatic diseases, including rheumatoid arthritis (RA), has significantly improved disease and functional…
Abstract Number: 1257 • ACR Convergence 2024
The Immune and Growth Characteristics of Children Born to Mothers with Systemic Lupus Erythematosus
Wenqiong Wang¹, Xiaodan Hu¹, Haoxiang Wang¹, Siyue Yu¹, Meng Xie¹, Shuming Shao¹, chun Li¹ and Jing He², ¹Peking University People's Hospital, Beijing, China, ²Rheumatology, Beijing, China
Background/Purpose: The aim of this study was to assess the immune, growth and development characteristics in offspring born to mothers with systemic lupus erythematosus (SLE).Methods:…
Abstract Number: 1283 • ACR Convergence 2024
Acute Transverse Myelitis in Pediatric Systemic Lupus Erythematosus
Meredith Rae¹, Emily Beil², Juan Carlos Torres², Kristen Fisher² and Eyal Muscal³, ¹Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine/Texas Children's Hospital, Houston, ³Baylor College of Medicine, Houston, TX
Background/Purpose: Transverse myelitis (TM) has an incidence of 1-2% in pediatric SLE and is often a feature of early disease. Most patients ( >60%) have…

« Previous Page
1
…
3
4
5
6
7
…
150
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.